Nightstar Therapeutics

What Nightstar Therapeutics does

Nightstar Therapeutics was a clinical-stage biopharmaceutical company founded in 2013 in London, United Kingdom, that developed gene therapies for retinal dystrophies, a class of inherited blinding diseases. The company's platform centered on adeno-associated virus (AAV)-based gene delivery to the eye, targeting conditions such as choroideremia and X-linked retinitis pigmentosa, both rare orphan indications with no approved disease-modifying treatments at the time. Nightstar operated with a small team (11-50 employees) and built its pipeline entirely through internal R&D, supported by approximately $99.8 million in disclosed equity financing across three rounds from 2014 to 2017, with New Enterprise Associates and Syncona Partners as anchor investors. The company completed an initial public offering on Nasdaq under ticker NITE and was subsequently acquired by Biogen in 2019, after which it has operated as a wholly-owned subsidiary of the larger biotech focused on neurology, immunology, and rare diseases.

The business model was a traditional clinical-stage biotech structure: capital was raised in successive venture rounds to fund preclinical research, IND-enabling studies, and clinical trials, with no product revenue and no commercial infrastructure of its own. The founder, Matthew J. During, a recognized gene therapy researcher, and CEO David Fellows led the company through its venture and public-market stages. The targeted patient population consisted of individuals with inherited retinal dystrophies, small orphan populations where a single successful therapy could command premium pricing under orphan drug frameworks. Post-acquisition, Nightstar's gene therapy assets, AAV manufacturing know-how, and clinical programs are integrated within Biogen's broader ophthalmology and rare disease strategy and distributed through Biogen's 35+ country commercial network across the Americas, Asia Pacific, Europe, and the Middle East. As a delisted subsidiary with no independent financial reporting, Nightstar's standalone commercial metrics, pipeline progression, and operating performance are no longer separately disclosed.

Name

Nightstar Therapeutics

Website

https://nightstartx.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Ophthalmic Gene Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmology Gene Therapies (HLAAACAG)

akta.pro secondary industry

Rare Ophthalmology Disorder Therapies (HLAIAIAK)

Keywords

• Gene therapy
• Retinal disease therapies
• Ophthalmic biopharmaceuticals
• Inherited retinal diseases
• Clinical-stage biopharma

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Product Sales: Biogen generates revenue through the sale of prescription pharmaceutical medicines for neurological, immunological, and rare diseases. The company manufactures and commercializes therapies across multiple disease areas including Multiple Sclerosis, Spinal Muscular Atrophy, Alzheimer's Disease, and Lupus.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Nightstar Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies for retinal dystrophies (inherited retinal diseases). Founded in 2013 in London, UK, the company focused on adeno-associated virus (AAV)-based gene therapies targeting ophthalmic conditions with high unmet need. Nightstar was acquired by Biogen in 2019.

Differentiator

Problem solved

Functional benefit

Products and services

• Gene therapies for retinal dystrophies

Quantifiable outcome

• Established pipeline across 8 disease areas including Alzheimer's, ALS, MS, and rare diseases

Segments8 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Biogen FoundationcoreOthersThe Biogen Foundation is a corporate foundation associated with Biogen, focused on philanthropy and social impact initiatives. It represents the company's charitable and community investment activities.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Spark Therapeutics: Pioneer in ophthalmology gene therapy, developer of Luxturna (the first FDA-approved gene therapy for an inherited retinal disease). Directly comparable to Nightstar on indication area, AAV delivery modality and orphan rare-disease go-to-market model; acquired by Roche in 2019.
• GenSight Biologics: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases, including Lumevoq (GS010) for Leber Hereditary Optic Neuropathy (LHON). Directly comparable in ophthalmology gene therapy approach and orphan rare-disease positioning.
• Applied Genetic Technologies Corp (AGTC): Clinical-stage company developing AAV-based gene therapies for inherited retinal diseases including X-linked retinitis pigmentosa and achromatopsia. Highly comparable on modality (AAV), indication space (retinal dystrophies) and development stage.
• MeiraGTx Holdings: Clinical-stage gene therapy company with inherited retinal disease programs (e.g., AAV-RPGR for X-linked retinitis pigmentosa, achromatopsia) and internal GMP manufacturing. Direct competitor to Nightstar in ophthalmology AAV gene therapy.
• REGENXBIO: Clinical-stage AAV gene therapy company with programs in wet AMD and other ophthalmology indications via its NAV Technology Platform. Closely comparable modality (AAV), therapeutic area overlap (eye) and pipeline stage.

Emerging players

• Editas Medicine: Clinical-stage gene editing company with ophthalmology programs (EDIT-101 for LCA10, an AAV-delivered CRISPR therapy). Comparable on inherited retinal disease focus and AAV delivery, though using gene editing rather than gene replacement.
• 4D Molecular Therapeutics: Clinical-stage gene therapy company with ophthalmology programs (e.g., 4D-125 for choroideremia, 4D-150 for wet AMD) using evolved AAV capsids. Competes directly in retinal dystrophy AAV gene therapy with novel vector engineering.
• Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (intravitreal AAV.7m8) for wet AMD and diabetic macular edema. Overlap with Nightstar on ocular AAV gene therapy delivery, though focused on more prevalent retinal vascular indications.
• IVERIC Bio (now Astellas): Developed gene therapy and complement-based therapies for inherited retinal diseases before being acquired by Astellas. Comparable rare ophthalmology franchise with overlap on indication space.

Broad incumbents

• Biogen: Nightstar's parent company and a major rare-disease/neurology biopharma. Relevant as the acquirer and ultimate commercialization channel; comparable on rare-disease pipeline depth and global distribution reach but not a direct product competitor in ophthalmology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/nightstar_x

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nightstar Therapeutics